See the DrugPatentWatch profile for Ingrezza
What is Ingrezza TD?
“Ingrezza TD” isn’t a single, widely used drug name on its own. It most likely refers to Ingrezza (valbenazine), and “TD” is commonly shorthand for tardive dyskinesia, the condition Ingrezza is prescribed to treat.
Ingrezza (valbenazine) is a vesicular monoamine transporter 2 (VMAT2) inhibitor used for tardive dyskinesia.
Why might people search “Ingrezza TD” specifically?
People often add “TD” when they’re trying to find information specifically for tardive dyskinesia treatment, such as:
- dosing and how to take it for TD
- expected timeline for improvement
- side effects that matter for TD patients
- whether it’s covered or which alternatives exist for TD
How does Ingrezza relate to other VMAT2 inhibitors for TD?
Ingrezza (valbenazine) is one of the VMAT2 inhibitors used in tardive dyskinesia. Another commonly discussed option is Austedo (deutetrabenazine). Searches for “Ingrezza TD” frequently come from people comparing these two for symptom control, tolerability, or insurance coverage.
Patent and exclusivity info for Ingrezza (valbenazine)
If you’re looking for patent or market exclusivity details for Ingrezza (valbenazine), DrugPatentWatch.com tracks such information and can be a useful starting point: DrugPatentWatch – Ingrezza (valbenazine)
Quick clarification (so I can answer exactly what you need)
What do you mean by “Ingrezza td”?
- TD as tardive dyskinesia (dose, side effects, timeline), or
- a specific formulation/brand you saw labeled “TD,” or
- patents/pricing info?
Reply with what you’re trying to learn (treatment details vs. patent/coverage), and I’ll tailor the answer.